FDA Clears Zepbound for Weight Loss

Look out, Wegovy and Ozempic–there’s a new weight loss drug in town! A recent CNN article noted that the FDA has officially approved the use of the type 2 diabetes drug tirzepatide, previously known as Mounjaro, for chronic weight management. Eli Lilly, the manufacturer of the drug, has renamed it "Zepbound" for its weight loss application. Zepbound demonstrated more than 20% average weight loss in clinical trials on higher doses over 72 weeks. It’s recommended for people with obesity or those characterized as overweight with at least one weight-related health condition.